Nervous System Diseases

Behaviors and Mental Disorders

All Conditions

Symptoms and General Pathology

Parasomnias

Dyssomnias

Sleep Wake Disorders

Mental Disorders

Psychotic Disorders

Participants will receive sleep restriction intervention

Sleep restriction

Participants will receive stimulus control intervention

Stimulus control

Participants will receive systematic light exposure intervention

Systematic light exposure

Rina S Fox, PhD, MPH

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

This study has two parts.

In Part 1, 15 gynecologic cancer survivors will receive three candidate intervention components known to reduce sleep disturbance (i.e., sleep restriction, stimulus control, systematic light exposure) simultaneously for six weeks. Participants will then complete semi-structured individual interviews to provide feedback about barriers to and facilitators of intervention adherence. Results of Part 1 will inform the design and delivery of the candidate components in Part 2.

In Part 2, a 2\^3 full factorial design will be followed to randomize 80 gynecologic cancer survivors to one of eight six-week intervention conditions reflecting all possible combinations of the three candidate intervention components.

Improving Sleep in Gynecologic Cancer Survivors

The night prior to each assessment participants will collect overnight urine to enable analysis of urinary 6-Sulfatoxymelatonin

Subjectively-reported sleep quality over the past 7 days will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Perceived impairment during wake associated with sleep problems over the past seven days will be measured with the PROMIS Sleep-Related Impairment questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

The 27-item Functional Assessment of Cancer Therapy - General (FACT-G) will measure HRQOL.

The 32-item Memorial Symptom Assessment Scale (MSAS) will evaluate symptom burden.

Symptoms of depression over the past seven days with be measured with the PROMIS Depression questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Symptoms of anxiety over the past seven days with be measured with the PROMIS Anxiety questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Fatigue over the past seven days with be measured with the PROMIS Fatigue questionnaire. Raw scores will be converted to T-scores with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the underlying construct.

Spots Global Cancer Trial Database for stimulus control